December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

41.09 +0.39 (+0.96%)
Official Closing Price Updated: 4:10 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? ↗
These stocks have been going in different directions over the past year, but that trend may not necessarily continue. 
Via The Motley Fool
News headline image
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide. ↗
The companies are competing in the weight loss drug market. 
Via The Motley Fool
News headline image
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now? ↗
Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step. 
Via The Motley Fool
News headline image
What Novo Nordisk A/S (NVO) Said on Its Q3 Earnings Call ↗
Novo Nordisk A/S (NYSE:NVO) raised its 2026 sales and profit outlook after third-quarter adjusted sales rose 4% to DKK 79.2 billion, supported by demand for its obesity treatments and expanding use of... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway? ↗
Novo got a much-needed boost from its latest earnings report. 
Via The Motley Fool
News headline image
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials ↗
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too. 
Via The Motley Fool
News headline image
2 Growth Stocks to Buy in November Without Any Hesitation ↗
They have both outperformed the broader equity market over the long run. 
Via The Motley Fool
News headline image
Novo Nordisk: 3 Key Takeaways for Long-Term Investors ↗
U.S. pricing pressure weighs on Novo Nordisk's growth, but management is counting on the pipeline to offset it over the long haul. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript ↗
Wegovy pill uptake and CagriSema trial results shape the growth recovery story. 
Via The Motley Fool
Topics Earnings
News headline image
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. ↗
Viking aims to enter the weight loss drug market. 
Via The Motley Fool
News headline image
3 Dirt Cheap Dividend Stocks to Buy in November 2026 ↗
These high-yielding stocks pay up to 7.4% in dividends. 
Via The Motley Fool
Topics Economy
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets 
From FN Media
Via GlobeNewswire
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge? ↗
Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to... 
Via MarketBeat
Topics ETFs
News headline image
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗
The market for GLP-1 drugs is forecast to explode. It may be understated still. 
Via The Motley Fool
News headline image
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. ↗
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech. 
Via The Motley Fool
News headline image
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? ↗
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point. 
Via The Motley Fool
News headline image
Novo Has Big Plans for 2030. Should You Buy the Stock Now? ↗
The company’s comeback strategy looks sound. 
Via The Motley Fool
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments. 
From FN Media
Via GlobeNewswire
News headline image
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? ↗
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story. 
Via The Motley Fool
News headline image
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility ↗
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors. 
Via The Motley Fool
News headline image
Where Will Novo Stock Be in 10 Years? ↗
The company may lean on its core therapeutic area to help it overcome recent headwinds. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? ↗
Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial. 
Via The Motley Fool
News headline image
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735. 
Via The Motley Fool
News headline image
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade? ↗
Novo is facing some headwinds, but it has a plan to overcome them. 
Via The Motley Fool
News headline image
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher ↗
Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine. 
Via The Motley Fool
News headline image
Novo Nordisk and Eli Lilly Just Got Some Fantastic News ↗
A new government-funded study found that GLP-1 drugs slow the aging process in mice. 
Via The Motley Fool
News headline image
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.